• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Surprise Enhertu rejection follows NICE process change

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 05, 2024 at 11:42: AM
via NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

article source
 




Top Bottom
Back
Quote